<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330927</url>
  </required_header>
  <id_info>
    <org_study_id>483-008</org_study_id>
    <nct_id>NCT01330927</nct_id>
  </id_info>
  <brief_title>Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Five-way Cross-over Dose Response Study to Determine the Effect of VA106483 on Nocturnal Urine Volume in Elderly Male Subjects With Nocturia and Benign Prostatic Hypertrophy (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vantia Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vantia Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the dose response relationship of VA106483 and
      nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic
      Hypertrophy (BPH) who are likely to present with nocturia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VA106483 is a selective vasopressin V2-receptor (V2-receptor) agonist that is being developed
      for the treatment of nocturia.

      The antidiuretic effect of V2-receptor stimulation in the kidneys is well established through
      the use of the peptide agonist, desmopressin, which shows clinical benefit in diabetes
      insipidus, primary nocturnal enuresis and nocturia.

      Nocturia, defined as waking to void at least once per night between periods of sleep, is a
      common complaint and shows an age-dependent increase in both prevalence and severity (number
      of nocturnal voids). It is the most bothersome symptom of benign prostatic hypertrophy and
      has been linked to an age-dependent loss in circadian release of endogenous nocturnal
      vasopressin and consequent over production of urine at night (nocturnal polyuria).

      Correlation between nocturnal urine volume and nocturnal void frequency has been demonstrated
      in previous studies of V2-receptor agonists.

      The purpose of this study is to determine the dose response relationship of VA106483 and
      nocturnal urine volumes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mean nocturnal urine volumes</measure>
    <time_frame>20 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the mean nocturnal void frequency</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean time to first void</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of daytime voids</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean volume of daytime voids</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean nocturnal urine osmolality</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean daytime urine osmolality</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean voided volumes</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Nocturia</condition>
  <condition>Benign Prostatic Hypertrophy (BPH)</condition>
  <arm_group>
    <arm_group_label>VA106483 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VA106483 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VA106483 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VA106483 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VA106483</intervention_name>
    <description>Once daily oral dose of placebo for 2 nights
Once daily oral dose of 0.5 mg VA106483 for 2 nights
Once daily oral dose of 1 mg VA106483 for 2 nights
Once daily oral dose of 2 mg VA106483 for 2 nights
Once daily oral dose of 4 mg VA106483 for 2 nights
Placebo: as above</description>
    <arm_group_label>VA106483 0.5 mg</arm_group_label>
    <arm_group_label>VA106483 1 mg</arm_group_label>
    <arm_group_label>VA106483 2 mg</arm_group_label>
    <arm_group_label>VA106483 4 mg</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males aged 65 years old and above with history of nocturia and benign prostatic
             hypertrophy (BPH)

        Exclusion Criteria:

          -  Administration of any Investigational Medicinal Product (IMP) within 10 weeks before
             entry to the study

          -  Any clinically significant concomitant medical disease, condition or abnormal
             laboratory test result

          -  Other protocol defined eligibility criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Golor, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Early Phase Clinical Unit, PAREXEL International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Hilary McElwaine-Johnn / Chief Medical Officer</name_title>
    <organization>Vantia Ltd, 1 Venture Road, Southampton Science Park, Southampton, SO16 7NP, UK</organization>
  </responsible_party>
  <keyword>VA106483</keyword>
  <keyword>Nocturia</keyword>
  <keyword>Benign Prostatic Hypertrophy</keyword>
  <keyword>BPH</keyword>
  <keyword>Elderly</keyword>
  <keyword>Males</keyword>
  <keyword>Nocturnal voids</keyword>
  <keyword>Anti-diuretic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Nocturia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

